Literature DB >> 17717563

Renal function outcomes following liver transplantation and combined liver-kidney transplantation.

Phuong-Thu T Pham1, Phuong-Chi T Pham, Alan H Wilkinson.   

Abstract

Acute renal failure (ARF) is common immediately after orthotopic liver transplantation (OLT), whereas the incidences of chronic kidney disease (CKD) and end-stage renal disease increase with time. Introduction of the Model for End-stage Liver Disease (MELD) score-intended to prioritize patients with more-severe pretransplantation liver disease in general, and worse pretransplantation renal function in particular-for the allocation of liver grafts led to concerns about compromised patient and allograft survival and increased incidence of postoperative ARF and CKD. Nonetheless, it has been suggested that early OLT of candidates with baseline renal dysfunction improves post-transplantation renal outcomes. For OLT candidates with mild to moderate chronic renal impairment or recent-onset ARF, the decision of whether to perform OLT alone or combined liver-kidney transplantation (CLKT) can be challenging because no single factor has been shown to be predictive of the degree of renal function recovery or CKD progression following successful OLT. In this article, we provide an overview of the literature on renal function outcomes following OLT and CLKT, share our perspectives on the potential predictors of renal dysfunction or nonrecovery of renal function after OLT, and present United Network for Organ Sharing data on patient and allograft outcomes in CLKT recipients in the pre-MELD and post-MELD eras. Mechanisms that might underlie immunological protection of kidney grafts by liver allografts are also discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17717563     DOI: 10.1038/ncpneph0574

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN: 1745-8323


  7 in total

1.  End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease.

Authors:  Ranjeeta Bahirwani; Kimberly A Forde; Yifei Mu; Fred Lin; Peter Reese; David Goldberg; Peter Abt; K Rajender Reddy; Matthew Levine
Journal:  Clin Transplant       Date:  2014-01-02       Impact factor: 2.863

Review 2.  Pre-transplant kidney function predicts chronic kidney disease after liver transplant: meta-analysis of observational studies.

Authors:  Fabrizio Fabrizi; Vivek Dixit; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2011-01-08       Impact factor: 3.199

3.  Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies.

Authors:  Yaojen Chang; Lorenzo Gallon; Kirti Shetty; Yuchia Chang; Colleen Jay; Josh Levitsky; Bing Ho; Talia Baker; Daniela Ladner; John Friedewald; Michael Abecassis; Gordon Hazen; Anton I Skaro
Journal:  Transplantation       Date:  2015-02       Impact factor: 4.939

4.  Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy.

Authors:  Yaojen Chang; Lorenzo Gallon; Colleen Jay; Kirti Shetty; Bing Ho; Josh Levitsky; Talia Baker; Daniela Ladner; John Friedewald; Michael Abecassis; Gordon Hazen; Anton I Skaro
Journal:  Liver Transpl       Date:  2014-09       Impact factor: 5.799

5.  Reduced impact of renal failure on the outcome of patients with alcoholic liver disease undergoing liver transplantation.

Authors:  Jaeyoun Cheong; Joseph A Galanko; Sumant Arora; Joaquin Cabezas; Nambi J Ndugga; Michael R Lucey; Paul H Hayashi; Alfred Sidney Barritt; Ramon Bataller
Journal:  Liver Int       Date:  2016-07-04       Impact factor: 5.828

6.  Risk Factors for the Incidence and Severity of Acute Kidney Injury After Liver Transplantation.

Authors:  Dali Zhang; Zhenwen Liu; Jing Feng Bi; Hongling Liu; Yinjie Gao
Journal:  Turk J Gastroenterol       Date:  2021-01       Impact factor: 1.555

7.  Predictors of renal recovery in patients with pre-orthotopic liver transplant (OLT) renal dysfunction.

Authors:  Jose Iglesias; Elliot Frank; Sushil Mehandru; John M Davis; Jerrold S Levine
Journal:  BMC Nephrol       Date:  2013-07-13       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.